| Catalog No. | HW299026 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Human |
|---|
| Isotype | IgG |
|---|
| Clone ID | KD014 |
|---|
| Biological activity |
KD014 (0.1-50 ug/mL; 3 days) has no effect on the viability of 4T1 or E0771 mouse breast cancer cells [1]. KD014 (0.2-100 ug/mL) significantly inhibits the invasive ability of 4T1 mouse breast cancer cells through type I collagen matrix in a dose-dependent manner [1]. KD014 (100-500 nM; 4 days) dose-dependently inhibits the degradation of collagen membranes by human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) [2]. KD014 (100-500 nM; 4 weeks) dose-dependently inhibits the invasion of bovine nasal cartilage by human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) [2]. Cell Invasion Assay [1] Cell Line: 4T1 murine breast carcinoma cells Concentration: 0.2, 2.0, 20, 100 ug/mL Incubation Time: / Result: Inhibited 4T1 cell invasion through a collagen matrix in a dose-dependent manner. Exhibited statistically significant inhibition at all tested concentrations (P =.0314 at 0.2 ug/mL to P =.0004 at 100 ug/mL). Cell Invasion Assay [2] Cell Line: human rheumatoid arthritis fibroblast-like synoviocytes (RA FLS) Concentration: 100 nM; 500 nM Incubation Time: 4 weeks Result: Inhibited the invasion of human RA FLS into bovine nasal cartilage explants in a dose-dependent manner, as shown by reduced presence of invading cells compared to control. KD014 (10 mg/kg; i.p.; once every 48 hours; up to 10 injections) inhibits tumor growth in 4T1 and E0771 orthotopic breast cancer mouse models [1]. KD014 (20-40 mg/kg; i.p.; once every other day for 10 days) significantly inhibits articular cartilage degradation and blocks arthritis progression in a mouse collagen-induced arthritis model [2]. |
| Expression system |
Mammalian cells |
| Clonality |
Monoclonal |
| Target |
MT-MMP 1, Matrix metalloproteinase-14, Membrane-type matrix metalloproteinase 1, Membrane-type-1 matrix metalloproteinase, MMP14, MTMMP1, MT1-MMP, MMP-14, MMP-X1, MT1MMP |
| Endotoxin level |
< 10 EU/mg |
| Purity |
>95% purity as determined by SDS-PAGE. |
| Purification |
Protein A/G purified from cell culture supernatant. |
| Accession |
P50281 |
| Form |
Liquid |
| Storage buffer |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternate Names | KD014, KD-014, KD014, DX-2400, DX2400, DX2400, DX-2410, DX2410, DX2410 |
|---|
| Background | Matrix metalloproteinase-14 (MMP14) is a ~65 kDa protein. Endopeptidase that degrades various components of the extracellular matrix such as collagen. Essential for pericellular collagenolysis and modeling of skeletal and extraskeletal connective tissues during development. Activates progelatinase A/MMP2, thereby acting as a positive regulator of cell growth and migration. Involved in the formation of the fibrovascular tissues in association with pro-MMP2. May be involved in actin cytoskeleton reorganization by cleaving PTK7. 2. Gu, G. et al. (2012) Journal of cellular biochemistry 113, 1013-21. PMID: 220653213. Noda, K. et al. (2003) Investigative ophthalmology & visual science 44, 2163-70. PMID: 127146574. Golubkov, VS. et al. (2010) The Journal of biological chemistry 285, 35740-9. PMID: 208374847. Chow, CFW. et al. (2022) Nature metabolism 4, 203-212. PMID: 35177851 |
|---|
| References |
1. Ager EI, et al. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J Natl Cancer Inst. 2015;107(4):djv017. Published 2015 Feb 20. [HW299026]
2. Kaneko K, et al. Selective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor Blockade. Arthritis Rheumatol. 2016 Feb;68(2):521-31. [HW299026]
3. Devy L, et al. Antitumor efficacy of DX-2400, a potent and selective human antibody MMP-14 inhibitor discovered using phage display technology. Cancer Research, 2007, 67(9_Supplement): 5618-5618. [HW299026] |
| Note |
For research use only. Not suitable for clinical or therapeutic use. |
中文
English
한국어
日本語
Español
Français
Русский
